NCT01484314 · ADVERSE EVENTS

Adverse events

Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma · Source last updated 2017-03-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: AE assessment was ongoing from the start of study drug and up to day 30 post-treatment. Due to privacy concerns with enrollment of one patient, no data is provided.
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Migration Arm Administration of eltrombopag to support platelets during chemotherapy Eltrombopag: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy	0 / 0	0 / 0	0 / 0

Group identifiers: EG000: Migration Arm

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

deaths Num Affected
0
deaths Num At Risk
0
description
Administration of eltrombopag to support platelets during chemotherapy Eltrombopag: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
id
EG000
other Num Affected
0
other Num At Risk
0
serious Num Affected
0
serious Num At Risk
0
title
Migration Arm

frequency Threshold

time Frame

AE assessment was ongoing from the start of study drug and up to day 30 post-treatment. Due to privacy concerns with enrollment of one patient, no data is provided.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice